Retatrutide ( Vigelan ) is a 39 amino acid single peptide with triple agonist activity at the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R)
However, some patients taking Wegovy experience gastrointestinal side effects such as nausea, vomiting, or indigestion, particularly when starting treatment or increasing the dose
They work closely with patients to develop treatment approaches that align with personal preferences and long-term health goals
According to NICE Technology Appraisal 875 (TA875) , Wegovy (semaglutide) is available on the NHS only through specialist weight management services and for adults who meet specific criteria, including: Generally, a body mass index (BMI) of 35 kg/m or greater with weight-related comorbidities (with lower thresholds for certain ethnic groups) Referral to and engagement with a specialist weight management service (Tier 3) Treatment limited to a maximum of 2 years This differs from the broader marketing authorisation criteria in the SmPC, which includes adults with a BMI of 30 kg/m or greater, or 27 kg/m or greater with weight-related comorbidities
